These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 33444901

  • 1. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M, Wang K, Zhu J, Lu Y, Huang M.
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [Abstract] [Full Text] [Related]

  • 2. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N.
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [Abstract] [Full Text] [Related]

  • 3. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ, Kim HR, Shim HS.
    J Transl Med; 2016 Oct 19; 14(1):296. PubMed ID: 27756333
    [Abstract] [Full Text] [Related]

  • 7. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.
    Indian J Cancer; 2017 Oct 19; 54(1):203-208. PubMed ID: 29199691
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 10. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
    Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia C, Jiang W, Hu Y, Liao D, Xiao L, Liu L, Yang H, Xiong Y, Guan R, Lizaso A, Mansfield AS, Yang N.
    J Thorac Oncol; 2020 Jun 08; 15(6):1027-1036. PubMed ID: 32112982
    [Abstract] [Full Text] [Related]

  • 11. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG, Seo S, Kim SW, Jang SJ, Park KS, Song JY, Lee B, Richards MW, Bayliss R, Lee DH, Choi J.
    Ann Oncol; 2017 Apr 01; 28(4):791-797. PubMed ID: 28039177
    [Abstract] [Full Text] [Related]

  • 12. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun 01; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 13. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing P, Zhang Z, Chuai S, Li J, Ying J.
    Lung Cancer; 2018 Apr 01; 118():128-133. PubMed ID: 29571990
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 01; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 18. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C, Barua S, Hsiao SJ, Mansukhani M, Saqi A, Murty V, Fernandes H.
    Cold Spring Harb Mol Case Stud; 2019 Jun 01; 5(3):. PubMed ID: 31160357
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.